A unifying model for multiple sclerosis

TL;DR

This paper proposes a new model for multiple sclerosis, suggesting a viral reactivation relay involving EBV and HHV-6A that leads to neurodegeneration and immune responses.

Contribution

The paper introduces a novel viral reactivation relay model for MS that integrates prior evidence and suggests new directions for prevention and therapy.

Findings

EBV reactivation in the brain precedes HHV-6A reactivation in oligodendrocytes and neurons.

Relapsing–remitting MS is linked to viral reactivation and CD8+T-cell-mediated inflammation.

Self-targeting antibodies may mark the onset of progressive MS in some patients.

Abstract

Multiple sclerosis (MS) is a complex neurodegenerative disorder with unresolved cause that has been the subject of intensive research. A variety of putative models have been proposed to explain the course of disease. The preeminent mechanisms are suggested to be based on autoimmunity, including via viral epitope mimicry, although difficulties with a classical autoimmunity model for MS have been described. One prior idea that incorporates consideration of viral–self-cross-reactivity is that reactivated HHV-6A virus might induce subsequent reactivation of another virus, EBV, in a relay, resulting in a cascade of downstream consequences. Here, an alternative model for MS is proposed. This posits a viral reactivation relay in which EBV reactivation in the brain precedes HHV-6A reactivation in oligodendrocytes and neurons. At this juncture, relapsing–remitting MS (RRMS) can ensue to generate characteristic lesions, dominated by outbreaks of viral reactivation and CD8+T-cell-mediated cytotoxicity and inflammation. Additionally, self-targeting antibodies can be raised to mark the onset of progressive MS in a subset of patients. This model harmonises a plethora of prior evidence from diverse fields. It is suggested that future studies should challenge this new model for MS and that it provides direction for future approaches to prevention and therapy.